Greater reductions in A1C in type 2 diabetic patients new to therapy with glyburide/metformin tablets as compared to glyburide co‐administered with metformin

Abstract

The lower medication doses delivered by glyburide/metformin tablets provided a significantly greater reduction in A1C than did glyburide co-administered with metformin in patients with type 2 diabetes, especially when baseline A1C >/= 8%.

Efficacy of Nateglinide and Pioglitazone Combination Therapy Compared With Monotherapy on Diabetic Nephropathy

“…Antidiabetic drug combinations are associated with improved compliance and improved glycemic control. FDC of sulfonylurea and rosiglitazone showed improved antidiabetic compliance and HbA1c levels and similar data also exists with glibenclamide and metformin 17,18 .…”

Fixed-Dose Combinations for Treatment of Type 2 Diabetes Mellitus

“…34 Among patients with T2DM using combination therapy, adherence tends to be greater with FDCs than with separate pills 21,31 and greater after switching from monotherapy to an FDC rather than to separate-pill combinations. 18,19,21 In the previously cited retrospective analysis by Thayer et al, adherence rates declined slightly among patients who were switched from monotherapy to combination therapy, but the decline was significantly smaller when switching to an FDC versus switching to separate-pill combinations.…”

Repaglinide/metformin fixed-dose combination to improve glycemic control in patients with type 2 diabetes: an update

“…These drugs include gemfibrozil, trimethoprim, itraconazole, ketoconazole and rifampin. Within 96 hours of dosing with 14 C-repaglinide, approximately 90% of the radiolabel is recovered in the feces and approximately 8% in the urine. Only 0.1% of the dose is cleared in the urine as parent compound and less than 2% in feces.…”

“…12 The concomitant use of repaglinide and metformin has been approved previously, but experience with other dual therapies suggests that fixed-dose combinations (FDCs) can provide greater patient compliance and thus better glycemic control than loose combinations. 13,14 Repaglinide/metformin FDC (PrandiMet ® ; Novo Nordisk, Bagsvaerd, Denmark) was approved by the Food and Drug Administration (FDA) in June 2008. Repaglinide/metformin FDC is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus who are already treated with a meglitinide and metformin or who have inadequate glycemic control on either meglitinide or metformin alone.…”